The British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem cell transplant (ASCT) should be considered for patients with greater than 12 months response to their first ASCT, and Velcade® should be administered as a subcutaneous rather than intravenous injection. The latest version is available on the BCSH website
